Beyond Air Pushes NO Therapies Amidst Zero Revenue
Ticker: XAIR · Form: 10-K · Filed: Jun 20, 2025 · CIK: 1641631
| Field | Detail |
|---|---|
| Company | Beyond Air, Inc. (XAIR) |
| Form Type | 10-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Biotechnology, Medical Devices, Clinical Trials, Nitric Oxide Therapy, Early Stage Company, SEC Filing, High Risk Investment
TL;DR
**Beyond Air is a high-risk, high-reward bet on unproven nitric oxide tech; avoid unless you're a long-term, speculative investor.**
AI Summary
Beyond Air, Inc. reported no revenue for the fiscal year ended March 31, 2025, consistent with the prior year, as the company remains in the clinical development stage. The net loss for the fiscal year was not explicitly stated in the provided data, but the company's focus on research and development for its LungFit platform indicates continued investment in future products. Key business changes include the ongoing development of the LungFit GO for bronchiolitis and LungFit PRO for various indications, with a strategic outlook centered on advancing these nitric oxide delivery systems through clinical trials. Risks include the inherent uncertainties of clinical trials, regulatory approvals, and the need for significant capital to fund operations, as evidenced by the company's continued reliance on financing. The company's strategic outlook is heavily dependent on successful clinical outcomes and subsequent commercialization of its nitric oxide therapies.
Why It Matters
Beyond Air's continued pursuit of nitric oxide therapies, despite zero revenue, highlights the high-stakes nature of biotech investing, where future potential outweighs current financials. Success with LungFit GO or LungFit PRO could revolutionize treatments for respiratory conditions, impacting patients, healthcare providers, and the competitive landscape for medical device companies. For investors, this filing underscores the long-term, speculative bet on clinical trial outcomes and regulatory approvals, contrasting sharply with established players in the surgical and medical instruments sector. Employees and customers are directly tied to the successful development and commercialization of these innovative, yet unproven, medical solutions.
Risk Assessment
Risk Level: high — Beyond Air, Inc. is a high-risk investment due to its lack of revenue for the fiscal year ended March 31, 2025, indicating it is still in the pre-commercialization phase. The company's operations are entirely dependent on the successful development and regulatory approval of its LungFit platform, which carries significant clinical trial and market adoption risks. The need for substantial capital to fund ongoing research and development, without a clear path to profitability, further elevates its risk profile.
Analyst Insight
Investors should approach Beyond Air with extreme caution, recognizing it as a highly speculative investment. Only those with a high-risk tolerance and a long-term horizon should consider a position, contingent on a deep dive into the specifics of their clinical trial progress and financing needs.
Financial Highlights
- revenue
- $0
- revenue Growth
- 0.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| LungFit Platform | $0 | 0.0% |
Key Numbers
- $0 — Revenue (No revenue reported for the fiscal year ended March 31, 2025, indicating pre-commercialization stage.)
- 2025-03-31 — Fiscal Year End (The period covered by this 10-K filing.)
- 0001641631 — Central Index Key (CIK) (Unique identifier for Beyond Air, Inc. with the SEC.)
- 3841 — SIC Code (Standard Industrial Classification for Surgical & Medical Instruments & Apparatus.)
- 2025-06-20 — Filed As Of Date (Date the 10-K was officially filed with the SEC.)
Key Players & Entities
- Beyond Air, Inc. (company) — filer of the 10-K
- LungFit GO (company) — product in development for bronchiolitis
- LungFit PRO (company) — product in development for various indications
- 001-38892 (regulator) — SEC file number
- 900 STEWART AVENUE (company) — business address street 1
- GARDEN CITY (company) — business address city
- NY (company) — business address state
- 11530 (company) — business address zip
- AIT Therapeutics, Inc. (company) — former company name
- KokiCare, Inc. (company) — former company name
FAQ
What is Beyond Air, Inc.'s primary business focus?
Beyond Air, Inc. is focused on developing and commercializing its LungFit platform, which delivers nitric oxide for various respiratory and infectious diseases, including bronchiolitis and other indications for LungFit PRO.
Did Beyond Air, Inc. generate revenue in the last fiscal year?
No, Beyond Air, Inc. reported zero revenue for the fiscal year ended March 31, 2025, indicating it remains in the clinical development stage without commercialized products generating sales.
What are the key products Beyond Air, Inc. is developing?
Beyond Air, Inc. is primarily developing LungFit GO for bronchiolitis and LungFit PRO for a range of other indications, both utilizing its nitric oxide delivery system.
What are the main risks for Beyond Air, Inc. investors?
The main risks for Beyond Air, Inc. investors include the inherent uncertainties of clinical trial success, obtaining regulatory approvals, and the significant capital required to fund operations without current revenue generation.
When was Beyond Air, Inc.'s 10-K filed?
Beyond Air, Inc.'s 10-K for the fiscal year ended March 31, 2025, was filed on June 20, 2025.
What is the significance of Beyond Air's zero revenue?
The zero revenue signifies that Beyond Air, Inc. is still a pre-commercialization company, heavily reliant on investor funding and the future success of its pipeline products, making it a high-risk, high-reward investment.
What is the fiscal year end for Beyond Air, Inc.?
Beyond Air, Inc.'s fiscal year ends on March 31, as indicated by the 'CONFORMED PERIOD OF REPORT: 20250331' in the filing.
Where is Beyond Air, Inc.'s business located?
Beyond Air, Inc.'s business address is 900 Stewart Avenue, Suite 301, Garden City, NY 11530.
What was Beyond Air, Inc. formerly known as?
Beyond Air, Inc. was formerly known as AIT Therapeutics, Inc. and prior to that, KokiCare, Inc.
How does Beyond Air, Inc.'s financial situation impact its strategic outlook?
Beyond Air, Inc.'s lack of revenue means its strategic outlook is entirely dependent on securing additional financing and achieving successful clinical trial outcomes and regulatory approvals for its LungFit platform to eventually generate sales.
Risk Factors
- Need for Additional Capital [high — financial]: The company's operations are heavily reliant on continued financing to fund its research and development activities and clinical trials. There is a significant risk that the company may not be able to secure sufficient capital, which could impact its ability to continue as a going concern.
- Clinical Trial and Regulatory Approval Uncertainty [high — regulatory]: Beyond Air's success is contingent upon the successful completion of clinical trials and subsequent approval from regulatory bodies such as the FDA. Delays, adverse results, or failure to obtain approval for LungFit GO and LungFit PRO would severely impact the company's prospects.
- Dependence on Key Personnel and Third Parties [medium — operational]: The company relies on a small team of key scientific and management personnel. Additionally, it depends on contract manufacturers for product development and manufacturing. Any disruption in these relationships could hinder progress.
- Market Adoption and Competition [medium — market]: Even if regulatory approvals are obtained, the commercial success of Beyond Air's nitric oxide delivery systems will depend on market acceptance and the ability to compete with existing therapies and potential new entrants in the respiratory care market.
Industry Context
Beyond Air operates in the medical device and biotechnology sector, specifically focusing on respiratory therapies. The market for respiratory treatments is competitive, with established players and emerging technologies. Key trends include the development of novel drug delivery systems and personalized medicine approaches for chronic and acute respiratory conditions.
Regulatory Implications
The company faces significant regulatory hurdles, primarily related to obtaining FDA approval for its LungFit platform. Successful navigation of the regulatory pathway is critical for commercialization. Any delays or failures in the approval process pose a substantial risk to the company's future.
What Investors Should Do
- Monitor clinical trial progress and regulatory updates.
- Assess future financing needs and sources.
- Evaluate competitive landscape and market adoption potential.
Key Dates
- 2025-03-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, covering financial performance and operational status.
- 2025-06-20: 10-K Filing Date — The date Beyond Air, Inc. officially submitted its annual report to the SEC, providing detailed financial and operational information.
- 2024-04-01: Start of Fiscal Year 2025 — Beginning of the period for which the 10-K report provides financial data.
- 2023-04-01: Start of Fiscal Year 2024 — Beginning of the prior fiscal year, useful for year-over-year comparisons.
Glossary
- LungFit platform
- Beyond Air's proprietary technology for delivering inhaled nitric oxide (iNO) for respiratory conditions. (This is the core product platform the company is developing and seeking regulatory approval for.)
- Nitric Oxide (NO)
- A molecule that plays a role in vasodilation and has potential therapeutic applications in respiratory diseases. (The active therapeutic agent in Beyond Air's LungFit products.)
- Bronchiolitis
- Inflammation of the small airways in the lungs, most common in infants and young children. (One of the key indications for which Beyond Air is developing its LungFit GO device.)
- Clinical Development Stage
- A phase in a company's lifecycle where it is conducting research and clinical trials to develop and test its products, typically before generating revenue. (Explains why Beyond Air has no revenue and is focused on R&D.)
- 10-K Filing
- An annual report required by the U.S. Securities and Exchange Commission (SEC) that gives a comprehensive summary of a company's financial performance. (The source document for this analysis, providing detailed company information.)
Year-Over-Year Comparison
For the fiscal year ended March 31, 2025, Beyond Air, Inc. reported no revenue, consistent with the prior year, as it remains in the clinical development stage. The company's focus on advancing its LungFit platform through clinical trials continues. No specific changes in key financial metrics like net income, EPS, or margins were provided in the initial data for comparison, but the overarching narrative of pre-commercialization and reliance on financing remains consistent.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on June 20, 2025 regarding Beyond Air, Inc. (XAIR).